Search for content, post, videos

Russian yes to simeprevir

The Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, announces Medivir.

Russia will be the first country within EMEA to gain access to simeprevir. “The Russian approval is another important event for simeprevir and provides the hepatitis C patients in Russia with a new HCV treatment” said Maris Hartmanis CEO, Medivir.

Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.